Study ID: ANB032-201. For eczema (atopic dermatitis)
Summary
This study is to test the safety and effectiveness of a novel injectable medication for eczema (also known as atopic dermatitis).
The study drug has the potential to be more effective
than topicals or creams at
treating moderate to severe eczema symptoms.
This medication is a biologic modifier
Injected into the body, it targets the pathways of the immune system to cut off the signal that stimulates eczema symptoms.
We are seeking volunteers with moderate to severe eczema that hasn’t improved with standard treatment options (topicals, creams).
This study will assess the efficacy of the study drug to:
Reduce the skin irritation and
other problems that atopic
dermatitis causes.
Moderate the overreaction in
your body’s immune system that
results in atopic dermatitis
symptom
Improve peoples’
overall quality
of life
Volunteers are needed to improve the outlook for other eczema patients globally.
If you have moderate to severe eczema, and want to help us research innovative treatments by trying them with us, read on to the inclusion criteria.
There are other criteria that our clinical staff will discuss with you as well.
Inclusion Criteria
You are eligible* to participate in the study if:
You are aged 18–65
You have been diagnosed with moderate-to-
severe atopic dermatitis (also referred to as
eczema) for at least 6 months
You have not found relief despite the use of
standard treatments for atopic dermatitis
You are in generally good health besides your
atopic dermatitis diagnosis
* Additional criteria for eligibility apply
If study investigators determine you are eligible, your participation may help find a potential treatment option for you and others with atopic dermatitis
If you participate in the ANB032-201 Study, You will be asked to:**
Provide signed informed consent
Comply with all scheduled clinic
visits and study-related
procedures
Not take any study-prohibited
medications during the trial
period
** Additional responsibilities apply
Your participation in the ANB032-201 Study is entirely voluntary, and your information will be confidential.
If you change your mind, you can withdraw from the study at any time, for any reason, and without any consequence
What to expect during the study
Beyond the initial screening period, the study lasts for about 36 weeks
consisting of 14 clinic visits to update on your health status, including:***
Routine laboratory
tests
Urinalysis
Physical Exam
Vital signs
Standard assessments for the severity of atopic dermatitis symptoms
The study lasts for about 40 weeks consisting of 15 clinic visits to update on your health status, including:
An initial Screening Period of up to 5 weeks with 1 clinic visit
You will undergo assessments to check if you fully qualify to participate in the study
A Treatment Period of 12 weeks with 7 clinic visits
At randomization and 6 additional visits, you will receive a dose of either ANB032-201 or an inactive placebo. Each dose consists of 2 injections under the skin
You or your doctor will not know if you received the active drug or the placebo until after the end of the study
A Follow-up Period of 24 weeks with 7 clinic visits
This includes follow-ups to ensure your well-being and measure your response to the doses you receive
***Additional assessments apply
Contact us about joining the trial
Fill out this form to get in touch.
We will contact you in 1-2 business days.